Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes

Sodium-glucose cotransporter 2 (SGLT2) inhibitor clinical studies in type 1 diabetes mellitus (T1DM) have demonstrated reduced HbA1c and lower glucose variability with increased time in optimal glucose range as well as additional benefits of reductions in weight and insulin dose without increasing t...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, Marc, Hicks, Debbie, Patel, Dipesh, Patel, Vinod, McEwan, Phil, Dashora, Umesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965597/
https://www.ncbi.nlm.nih.gov/pubmed/31813092
http://dx.doi.org/10.1007/s13300-019-00728-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965597/
https://www.ncbi.nlm.nih.gov/pubmed/31813092
http://dx.doi.org/10.1007/s13300-019-00728-6

Ejemplares similares